Self-adjuvanting polyacrylic nanoparticulate delivery system for group A streptococcus (GAS) vaccine

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 7, Issue 2, 2011, Pages 168-173

  Zaman, Mehfuz ^a   Skwarczynski, Mariusz ^a   Malcolm, Jessica M ^b   Urbani, Carl N ^a   Jia, Zhongfan ^a   Batzloff, Michael R ^b   Good, Michael F ^b   Monteiro, Michael J ^a   Toth, Istvan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Dendrimer; Group A Streptococcus; Intranasal immunization; Self adjuvanting vaccine; Self assembled nanoparticles

Indexed keywords

AUSTRALIA; C-TERMINAL REGIONS; DELIVERY SYSTEMS; DENDRITIC POLYMERS; GLOBAL HEALTH; GROUP A STREPTOCOCCUS; IN-VITRO; INTRANASAL; INTRANASAL IMMUNIZATION; NANO PARTICULATES; RHEUMATIC HEART DISEASE; SELF-ADJUVANTING VACCINE; SELF-ASSEMBLED NANOPARTICLES; STREPTOCOCCUS PYOGENES; SUBUNIT VACCINE; SYNTHETIC PEPTIDE; VACCINE DELIVERY; VACCINE DEVELOPMENT;

CARDIOLOGY; DENDRIMERS; IMMUNIZATION; NANOPARTICLES; PEPTIDES; VACCINES;

DISEASES;

CHOLERA TOXIN B SUBUNIT; IMMUNOGLOBULIN G ANTIBODY; J14 DENDRIMER VACCINE; POLYACRYLIC ACID; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; MOUSE; NONHUMAN; OPSONIZATION; STREPTOCOCCUS GROUP A; VACCINATION;

ACRYLIC RESINS; ADMINISTRATION, INTRANASAL; ANIMALS; CHEMOTHERAPY, ADJUVANT; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; MICE; NANOMEDICINE; NANOPARTICLES; OPSONIN PROTEINS; PEPTIDES; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES;

STREPTOCOCCUS PYOGENES; STREPTOCOCCUS SP. 'GROUP A';

EID: 79952747701     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2010.10.002     Document Type: Article

References (49)

1. Black M., Trent A., Tirrell M., Olive C. Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonists. Expert Rev Vaccines 2010, 9:157-173.
2. Olive C. Progress in M-protein-based subunit vaccines to prevent rheumatic fever and rheumatic heart disease. Curr Opin Mol Ther 2007, 9:25-34.
3. Carapetis J.R., Currie B.J. Group A streptococcus, pyoderma, and rheumatic fever. Lancet 1996, 347:1271-1272.
4. Carapetis J.R., Wolff D.R., Currie B.J. Acute rheumatic fever and rheumatic heart disease in the top end of Australia's Northern Territory. Med J Aust 1996, 164:146-149.
5. Carapetis J.R., Walker A.M., Hibble M., Sriprakash K.S., Currie B.J. Clinical and epidemiological features of group A streptococcal bacteraemia in a region with hyperendemic superficial streptococcal infection. Epidemiol Infect 1999, 122:59-65.
6. McDonald M., Currie B.J., Carapetis J.R. Acute rheumatic fever: a chink in the chain that links the heart to the throat?. Lancet Infect Dis 2004, 4:240-245.
7. Gladstone P., Varghese G., Brahmadathan K.N. Dynamics of anti-M antibody response in a mouse model following intranasal infection with group A Streptococcus M-18. J Med Microbiol 2005, 54:305-308.
8. Smeesters P.R., Mardulyn P., Vergison A., Leplae R., Van Melderen L. Genetic diversity of Group A Streptococcus M protein: implications for typing and vaccine development. Vaccine 2008, 26:5835-5842.
9. Quinn A., Kosanke S., Fischetti V.A., Factor S.M., Cunningham M.W. Induction of autoimmune valvular heart disease by recombinant streptococcal m protein. Infect Immun 2001, 69:4072-4078.
10. Guilherme L., Faé K.C., Oshiro S.E., Tanaka A.C., Pomerantzeff P.M., Kalil J. T cell response in rheumatic fever: crossreactivity between streptococcal M protein peptides and heart tissue proteins. Curr Protein Pept Sci 2007, 8:39-44.
11. Faé K.C., Oshiro S.E., Toubert A., Charron D., Kalil J., Guilherme L. How an autoimmune reaction triggered by molecular mimicry between streptococcal M protein and cardiac tissue proteins leads to heart lesions in rheumatic heart disease. J Autoimmun 2005, 24:101-109.
12. Pruksakorn S., Currie B., Brandt E., Martin D., Galbraith A., Phornphutkul C., et al. Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci. Lancet 1994, 344:639-642.
13. Brandt E.R., Hayman W.A., Currie B., Carapetis J., Wood Y., Jackson D.C., et al. Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci. Immunology 1996, 89:331-337.
14. Brandt E.R., Hayman W.A., Currie B., Pruksakorn S., Good M.F. Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci. Vaccine 1997, 15:1805-1812.
15. Pruksakorn S., Currie B., Brandt E., Phornphutkul C., Hunsakunachai S., Manmontri A., et al. Identification of T cell autoepitopes that cross-react with the C-terminal segment of the M protein of group A streptococci. Int Immunol 1994, 6:1235-1244.
16. Hayman W.A., Brandt E.R., Relf W.A., Cooper J., Saul A., Good M.F. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int Immunol 1997, 9:1723-1733.
17. Relf W.A., Cooper J., Brandt E.R., Hayman W.A., Anders R.F., Pruksakorn S., et al. Mapping a conserved conformational epitope from the M protein of group A streptococci. Pept Res 1996, 9:12-20.
18. Vohra H., Dey N., Gupta S., Sharma A.K., Kumar R., McMillan D., et al. M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats. Res Microbiol 2005, 156:575-582.
19. Shaila M.S., Nayak R., Prakash S.S., Georgousakis M., Brandt E., McMillan D.J., et al. Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles. Vaccine 2007, 25:3567-3573.
20. Batzloff M.R., Hayman W.A., Davies M.R., Zeng M., Pruksakorn S., Brandt E.R., et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis 2003, 187:1598-1608.
21. Pandey M., Batzloff M.R., Good M.F. Mechanism of protection induced by group A streptococcus vaccine candidate J8-DT: contribution of B and T-cells towards protection. PLoS One 2009, 4:e5147.
22. Renjifo X., Wolf S., Pastoret P.P., Bazin H., Urbain J., Leo O., et al. Carrier-induced, hapten-specific suppression: a problem of antigen presentation?. J Immunol 1998, 161:702-706.
23. Burrage M., Robinson A., Borrow R., Andrews N., Southern J., Findlow J., et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun 2002, 70:4946-4954.
24. McNeil S.A., Halperin S.A., Langley J.M., Smith B., Warren A., Sharratt G.P., et al. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005, 41:1114-1122.
25. Olive C., Moyle P.M., Toth I. Towards the development of a broadly protective group a streptococcal vaccine based on the Lipid-Core Peptide system. Curr Med Chem 2007, 14:2976-2988.
26. Abdel-Aal A.B., Batzloff M.R., Fujita Y., Barozzi N., Faria A., Simerska P., et al. Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group A streptococcal vaccine candidates. J Med Chem 2008, 51:167-172.
27. Brandt E.R., Sriprakash K.S., Hobb R.I., Hayman W.A., Zeng W., Batzloff M.R., et al. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nat Med 2000, 6:455-459.
28. Dunn L.A., McMillan D.J., Batzloff M., Zeng W., Jackson D.C., Upcroft J.A., et al. Parenteral and mucosal delivery of a novel multi-epitope M protein-based group A streptococcal vaccine construct: investigation of immunogenicity in mice. Vaccine 2002, 20:2635-2640.
29. Batzloff M.R., Hartas J., Zeng W., Jackson D.C., Good M.F. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. J Infect Dis 2006, 194:325-330.
30. Georgousakis M.M., McMillan D.J., Batzloff M.R., Sriprakash K.S. Moving forward: a mucosal vaccine against group A streptococcus. Expert Rev Vaccines 2009, 8:747-760.
31. BenMohamed L., Wechsler S.L., Nesburn A.B. Lipopeptide vaccines-yesterday, today, and tomorrow. Lancet Infect Dis 2002, 2:425-431.
32. Ranasinghe C., Turner S.J., McArthur C., Sutherland D.B., Kim J.H., Doherty P.C., et al. Mucosal HIV-1 pox virus prime-boost immunization induces high-avidity CD8+ T cells with regime-dependent cytokine/granzyme B profiles. J Immunol 2007, 178:2370-2379.
33. Pincock S. Indigenous health in Australia still lagging. Lancet 2008, 372:18.
34. Raman S., Machaidze G., Lustig A., Aebi U., Burkhard P. Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles. Nanomedicine 2006, 2:95-102.
35. Kabanov A.V. From synthetic polyelectrolytes to polymer subunit vaccines. Pure Appl Chem 2004, 76:1659-1677.
36. Hilgers L.A., Ghenne L., Nicolas I., Fochesato M., Lejeune G., Boon B. Alkyl-polyacrylate esters are strong mucosal adjuvants. Vaccine 2000, 18:3319-3325.
37. Hilgers L.A., Nicolas I., Lejeune G., Dewil E., Boon B. Effect of various adjuvants on secondary immune response in chickens. Vet Immunol Immunopathol 1998, 66:159-171.
38. Kusonwiriyawong C., van de Wetering P., Hubbell J.A., Merkle H.P., Walter E. Evaluation of pH-dependent membrane-disruptive properties of poly(acrylic acid) derived polymers. Eur J Pharm Biopharm 2003, 56:237-246.
39. Zaman M., Simerska P., Toth I. Synthetic polyacrylate polymers as particulate intranasal vaccine delivery systems for the induction of mucosal immune response. Curr Drug Deliv 2010, 7:118-124.
40. Whittaker M.R., Urbani C.N., Monteiro M.J. Synthesis of 3-miktoarm stars and 1st generation mikto dendritic copolymers by ″ living″ radical polymerization and ″ click″ chemistry. J Am Chem Soc 2006, 128:11360-11361.
41. Skwarczynski M., Zaman M., Urbani C., Lin I.C., Jia Z., Batzloff M.R., et al. Novel self-adjuvanting vaccine delivery system: polyacrylate dendrimer nanoparticles. Angew Chem Int Edn 2010, 49:5742-5745.
42. Stevens T.L., Bossie A., Sanders V.M., Fernandez-Botran R., Coffman R.L., Mosmann T.R., et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988, 334:255-258.
43. Aspord C., Thivolet C. Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice. Clin Exp Immunol 2002, 130:204-211.
44. Kalish M.L., Check I.J., Hunter R.L. Murine IgG isotype responses to the Plasmodium cynomolgi circumsporozoite peptide (NAGG)5. I. Effects of carrier, copolymer adjuvants, and lipopolysaccharide on isotype selection. J Immunol 1991, 146:3583-3590.
45. Nimmerjahn F., Ravetch J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005, 310:1510-1512.
46. Ey P.L., Prowse S.J., Jenkin C.R. Complement-fixing IgG1 constitutes a new subclass of mouse IgG. Nature 1979, 281:492-493.
47. Steer A.C., Carapetis J.R., Nolan T.M., Shann F. Systematic review of rheumatic heart disease prevalence in children in developing countries: the role of environmental factors. J Paediatr Child Health 2002, 38:229-234.
48. Brandt E.R., Teh T., Relf W.A., Hobb R.I., Good M.F. Protective and nonprotective epitopes from amino termini of M proteins from Australian aboriginal isolates and reference strains of group A streptococci. Infect Immun 2000, 68:6587-6594.
49. Amela I., Cedano J., Querol E. Pathogen proteins eliciting antibodies do not share epitopes with host proteins: a bioinformatics approach. PLoS One 2007, 2:e512.